● Recruiting

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

Condition: Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma · Sponsor: Chinese PLA General Hospital

PhasePhase 1/Phase 2

Planned participants30

Who can joinAll sexes, 16 Years to 80 Years

Healthy volunteersNo

About this study

Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors. In this trial, CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma will be treated by CD30-specific CART cells (CART30).

This description comes directly from the study's public registry record.

Talk to the study team

Weidong Han, Ph.D · 86-10-66937463 · hanwdrsw@sina.com

Quanshun Wang, Ph.D · 86-10-66939486 · wqs63@sohu.com

Always discuss trial participation with your own doctor first.

Locations (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02259556